ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

AUPH vs IMNM // OPTIONS IMPLIED MOVE & PUT/CALL SKEW

Aurinia Pharmaceuticals Inc (NASDAQ) VS. Immunome Inc. (NASDAQ) • 15-METRIC TALLY: AUPH 8 — IMNM 1
■ METRIC PARITY
options-implied-move
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (AUPH VS. IMNM) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC AUPH IMNM SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 88.50% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) 16.50% -35.00% +51.50 AUPH /roic <GO>
EV/EBITDA & P/E Valuation 21.1x — — TIE /valuation <GO>
Free Cash Flow Yield 5.92% -9.29% +15.21 AUPH /fcf-yield <GO>
Operating Margin 37.10% -60.00% +97.10 AUPH /operating-margins <GO>
Net Profit Margin 68.00% -60.00% +128.00 AUPH /net-margins <GO>
Revenue Growth (YoY) 20.40% -23.20% +43.60 AUPH /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity 8.33 25.03 -16.70 IMNM /balance-sheet <GO>
Piotroski F-Score Quality 7/9 3/9 +4.00 AUPH /piotroski-score <GO>
Options Implied Move & Put/Call Skew ACTIVE — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 49.1 39.7 +9.40 AUPH /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple 6.7x — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $2.22B $2.15B $66.5M AUPH /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR AUPH REV IMNM REV AUPH GROSS % IMNM GROSS % AUPH FCF IMNM FCF
FY 2025 $283.1M $6.9M 88.5% — $135.7M -$200.6M
FY 2024 $235.1M $9.0M 88.0% — $44.4M -$118.0M
FY 2023 $175.5M $14.0M — — -$33.5M -$7.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
AUPH // BETA —
IMNM // BETA —